相关实验视频

Updated: Jan 13, 2026

Author Spotlight: Accelerating Discovery in Microporous Material Chemistry

Author Spotlight: Accelerating Discovery in Microporous Material Chemistry

Published on: October 6, 2023

通过充电链接器修改优化基于PSMA-617的抑制剂:深入了解结构-活性关系

Nicolas M Geis^1,2,3, Yvonne Braunwarth^1,2, Philipp T Meyer¹

¹Department of Nuclear Medicine, University Medical Center Freiburg, Faculty of Medicine, University of Freiburg, Hugstetter Str. 55, 79106 Freiburg, Germany.

|January 9, 2026

概括

用histidine和谷氨酸修改PSMA-617改变了它的特性,改善了前临床前列腺癌模型中的瘤吸收和清除. 需要进一步的研究来评估治疗潜力和非目标效应.

科学领域:

放射性药物化学放射性药物化学
核医学就是核医学.
前列腺癌研究研究前列腺癌

背景情况:

普鲁维克托 (Pluvicto®) ([177Lu]Lu-vipivotide tetraxetan) 是一种用于治疗PSMA阳性转移性割耐性前列腺癌 (mCRPC) 的关键放射性联体疗法.
[177Lu]Lu-PSMA-617和α-发射物的剂量升级提高了疗效,但受到脏和唾液腺等器官毒性的限制.
对PSMA抑制剂的链接区域的修改可以显著影响它们的药理动力学特征.

研究的目的:

合成和评估新型PSMA-617变体与histidine和/或谷氨酸修饰在链接区域.
研究这些修改对药物动力学特性,结合亲和力和细胞吸收的影响.
用小动物PET成像来评估这些新型化合物的体内行为.

主要方法:

根据PSMA-617结构合成了11种新型PSMA向抑制剂,其中包括histidine和/或谷氨酸部分.
化合物被放射性标记为[68Ga]Ga3+和[177Lu]Lu3+以进行稳定性和性质评估.
实验室评估包括使用LNCaP细胞进行竞争性细胞结合和内化试验.
在体内研究涉及动态和静态小动物PET成像与68Ga标记的抑制剂在LNCaP异种移植.

主要成果:

与基准相比,放射性标记化合物具有较高的放射性化学纯度 (>94%) 和降低的脂性.
这些修改显著影响了PSMA亲和力 (IC50:10.40±2.94nM至78.6±44.1nM).
使用谷氨酸或西丁-谷氨酸的变体显示了增强的结合,内化,瘤积累 (SUV1h:0.21 ± 0.05至1.32 ± 0.08 g/ml),并在60分钟内从脏和背景组织迅速清除.

结论:

在PSMA-617链接器中的histidine和/或谷氨酸修饰改变了体外和体内的药理动力学特性.
一些变体表现出改善的瘤脏比率和有利的早期分泌特征.
预测临床脱效应,如唾液腺吸收,仍然是一个挑战,需要进一步的机制和翻译研究来评估治疗潜力.

关键词:

在PSMA上,PSMA可以在PSMA上进行交易.被指控的链接者链接器修改-修改药物动力学概况药物动力学概况前列腺癌是前列腺癌.

更多相关视频

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

相关概念视频

Adrenergic Agonists: Chemistry and Structure-Activity Relationship

Adrenergic Agonists: Chemistry and Structure-Activity Relationship

Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...

Structure-Activity Relationships and Drug Design

Structure-Activity Relationships and Drug Design

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...